1
by Jahagirdar, Deepa, Campbell, Kaitryn
Published 2018
CADTH
... to other supportive interventions or opioid substitution therapies. Further, there may be differences...

2
by Jahagirdar, Deepa, Campbell, Kaitryn
Published 2018
CADTH
... to other supportive interventions or opioid substitution therapies. Further, there may be differences...

3
by Klarenbach, Scott, So, Helen, Manns, Braden, Tonelli, Marcello
Published 2017
Canadian Agency for Drugs and Technologies in Health
... have suggested there may be differences in their clinical effectiveness and safety, including risks...

4
by Tran, Khai, Ryce, Andrea
Published 2018
CADTH
...Recent systematic review and meta-analysis found no significant differences in visual outcomes...

5
by Tran, Khai, Ryce, Andrea
Published 2018
CADTH
...Recent systematic review and meta-analysis found no significant differences in visual outcomes...

6
Published 2018
Canadian Agency for Drugs and Technologies in Health
... of the DAPT Score combined with consideration of findings from a recent clinical review that found different...

7
Published 2021
Canadian Agency for Drugs and Technologies in Health
... hydrochloride sublingual (APO SL) film. Aligned with the CADTH Clinical Review, given no differences in clinical...

8
Published 2018
Canadian Agency for Drugs and Technologies in Health
... of the DAPT Score combined with consideration of findings from a recent clinical review that found different...

9
Published 2011
Canadian Agency for Drugs and Technologies in Health
... strategies in Canada. 4. Identify differences (i.e., the gaps) between optimal prescribing and use of AAP...

10
Published 2018
Canadian Agency for Drugs and Technologies in Health
... the infusion, or dies during the waiting period after leukapheresis. Differences in the practice and use of CAR...

11
Published 2011
Canadian Agency for Drugs and Technologies in Health
... strategies in Canada. 4. Identify differences (i.e., the gaps) between optimal prescribing and use of AAP...

12
Published 2018
Canadian Agency for Drugs and Technologies in Health
... the infusion, or dies during the waiting period after leukapheresis. Differences in the practice and use of CAR...

13
Published 2017
Canadian Agency for Drugs and Technologies in Health
... no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective...

14
Published 2017
Canadian Agency for Drugs and Technologies in Health
... no apparent differences in efficacy across drug classes, and that sulfonylureas were the most cost-effective...

15
Published 2021
Canadian Agency for Drugs and Technologies in Health
... for satralizumab plus IST compared with IST alone, CADTH further assumed no differences in the frequency of adverse...

16
Published 2013
Canadian Agency for Drugs and Technologies in Health

17
Published 2013
Canadian Agency for Drugs and Technologies in Health

18
by Kaulback, Kellee, Jones, Sarah, Wells, Charlotte, Felipe, Eldiflor
Published 2017
Canadian Agency for Drugs and Technologies in Health
... controlled trials (RCTs) were meta-analyzed, no clinically important differences of HA treatment over IA...

19
Published 2021
Canadian Agency for Drugs and Technologies in Health
...Previous studies in different clinical settings have shown that valuation of health states...